Coinbase CEO Brian Armstrong predicts Bitcoin could reach between $300,000 and $400,000 by 2030 if it follows historical four-year market cycles and halving events. These halvings reduce new Bitcoin supply and have previously led to major price advances and corrections. Armstrong noted Bitcoin may have recently bottomed around $60,000 in its latest cycle phase, but he cautioned that future market behavior is uncertain. He also emphasized that Bitcoin is just one part of the crypto ecosystem, with other sectors like stablecoins and decentralized finance continuing to evolve regardless of Bitcoin's price movements.
Coinbase CEO Brian Armstrong's Bitcoin forecast is presented alongside Pluang's cryptocurrency market data. For readers following crypto, here is Pluang's market snapshot as of Sep 30, 2026 04:03 WIB: out of 50 major cryptocurrencies, 29 rose and 20 fell. Notable movers include SXP at Rp37 with a -46.27% change, AAVE at Rp2.982.902 with a +12.44% change and 97% sell order activity, and BAL at Rp16.297 with an +11.14% change.
GameStop's CEO Ryan Cohen and other executives have made significant insider purchases of millions of shares, showing strong confidence in the company's future despite recent stock price volatility. These buys were active decisions, not pre-scheduled...
Concentrix Corporation reported mixed Q3 2026 results with earnings per share of $2.92, beating analyst expectations of $2.71. However, its revenue of $2.45 billion slightly missed the forecast of $2.48 billion. The company achieved a record free cas...
Accenture is set to report Q3 2026 earnings on October 1, with analysts forecasting $18.03 billion in revenue, a 5.6% increase year-over-year, and earnings per share around $3.18. The growth is fueled by strong demand for AI services, with 100 new ad...
Iovance Biotherapeutics shares jumped 31.48% after raising its 2026 revenue forecast, driven by strong demand for its cancer immunotherapy Amtagvi. SoundThinking's stock rose 50.09% following an acquisition agreement with Transom Capital Group, offer...
Shares of uniQure dropped 37.33% following mixed clinical data for its Huntington's disease gene therapy. Fair Isaac fell 26.52% after U.S. regulators expanded the use of competitor VantageScore in mortgage credit scoring, threatening its market posi...
